Sedivention, a Berlin-based medtech startup developing a minimally invasive obesity treatment, has raised €2.9 million in seed funding. The round was led by bmp Ventures with the IBG funds, with participation from High-Tech Gründerfonds, Cambridge Ventures, superangels, and the investment arm of an international MedTech company.
The company is developing a one-time outpatient therapy for obesity based on a proprietary cryo-balloon catheter. The procedure is designed to be performed without surgery, implants, or long-term medication, positioning it as a device-based alternative in a fast-growing obesity treatment market.
Sedivention said the new capital will be used to further develop the therapy, generate initial clinical data for market entry, complete product development, conduct a first-in-human study, and prepare regulatory requirements for commercialization.
The financing comes as investors and healthcare companies continue to look for new approaches to obesity care beyond bariatric surgery and chronic drug treatment.
The company is developing a one-time outpatient therapy for obesity based on a proprietary cryo-balloon catheter. The procedure is designed to be performed without surgery, implants, or long-term medication, positioning it as a device-based alternative in a fast-growing obesity treatment market.
Sedivention said the new capital will be used to further develop the therapy, generate initial clinical data for market entry, complete product development, conduct a first-in-human study, and prepare regulatory requirements for commercialization.
The financing comes as investors and healthcare companies continue to look for new approaches to obesity care beyond bariatric surgery and chronic drug treatment.